Study questions Paxlovid’s COVID-19 ‘usefulness’

Press/Media: Expert Comment

Description

Researchers say the antiviral does little to reduce symptom duration for some vaccinated patients, but still recommended its use for the vulnerable

Subject

COVID-19

Antiviral medication

Period11 Apr 2024

Media contributions

1

Media contributions

  • TitleStudy questions Paxlovid’s COVID-19 ‘usefulness’
    Degree of recognitionNational
    Media name/outletNewsGP
    Media typeWeb
    Country/TerritoryAustralia
    Date11/04/24
    DescriptionResearchers say the antiviral does little to reduce symptom duration for some vaccinated patients, but still recommended its use for the vulnerable...
    Professor Mark Morgan, Chair of RACGP Expert Committee – Quality Care, told newsGP it remains unclear why these trial results were not published earlier.

    ‘The numbers of participants and between group differences were too small to be clear if this difference occurred by chance or because of the treatment,’ he said.

    ‘Similarly, there was no difference in the rates of viral load rebound or symptoms rebound after completion of the course of Paxlovid.’
    Producer/AuthorMichelle Wisbey
    URLhttps://www1.racgp.org.au/newsgp/clinical/study-questions-paxlovid-s-covid-19-usefulness?utm_source=racgpnewsgpnewsletter&utm_campaign=newsgpedm&utm_medium=email
    PersonsMark Morgan